Interim / Quarterly Report • Jul 20, 2023
Interim / Quarterly Report
Open in ViewerOpens in native device viewer



(compared with the corresponding period a year ago)
| SEKm | 2306 | 2206 | % | 2023:2 | 2022:2 | % |
|---|---|---|---|---|---|---|
| Net sales | 86,856 | 72,230 | 20 | 43,930 | 37,929 | 16 |
| Adjusted operating profit before amortization of acquisition related intangible assets (EBITA)1 |
9,059 | 5,984 | 51 | 4,701 | 3,158 | 49 |
| Operating profit before amortization of acquisition-related intangible assets (EBITA) |
8,660 | 4,313 | 101 | 4,215 | 2,650 | 59 |
| Amortization of acquisition-related intangible assets | -567 | -539 | -281 | -276 | ||
| Adjusted operating profit1 | 8,492 | 5,445 | 56 | 4,420 | 2,882 | 53 |
| Items affecting comparability | -432 | -1,928 | -519 | -515 | ||
| Operating profit | 8,060 | 3,517 | 129 | 3,901 | 2,367 | 65 |
| Financial items | -1,288 | -432 | -633 | -224 | ||
| Profit before tax | 6,772 | 3,085 | 120 | 3,268 | 2,143 | 52 |
| Adjusted profit before tax1 | 7,204 | 5,013 | 44 | 3,787 | 2,658 | 42 |
| Income taxes | -1,518 | -891 | -717 | -470 | ||
| Profit for the period | 5,254 | 2,194 | 139 | 2,551 | 1,673 | 52 |
| Earnings per share, SEK | 7.32 | 2.55 | 3.53 | 2.11 | ||
| Adjusted earnings per share, SEK2 | 8.31 | 5.69 | 4.33 | 2.97 |
1Excluding items affecting comparability; for amounts see page 13.
2Excluding items affecting comparability and amortization of acquisition-related intangible assets.

Essity performed well in the second quarter with continued high sales growth and higher margins. We are following our plan to achieve our target of a return on capital employed of above 17% by 2025. Essity has now completely exited the Russian market and the ongoing strategic review of ownership in Vinda and Consumer Tissue Private Label Europe is proceeding according to plan.
During the second quarter, net sales increased 15.8% and sales growth, including organic sales growth and acquisitions, amounted to 8.7%. Sales prices were higher and the product mix was better. The lower volumes are mainly the result of our focus on margin improvement, resulting in us exiting certain volumes with unsatisfactory profitability. Adjusted EBITA increased by 49% and the adjusted EBITA margin by 2.4 percentage points to 10.7%. The margin was positively impacted by higher selling prices, a better mix and cost savings. Earnings per share increased to SEK 3.53.
Since the start of Russia's war against Ukraine, we have been fully focused on exiting Russia. Work commenced in April 2022 and this has now been completed.
During the quarter, a strategic review was initiated of our ownership in the Asian hygiene company Vinda and Consumer Tissue Private Label Europe with the aim of reducing Consumer Tissue's share of the company's total sales. The process is proceeding according to plan and various options are being explored that may result in divestments, although no such decisions have yet been taken. Excluding these businesses, Essity's organic sales growth would have amounted to 8.0% and the adjusted EBITA margin to 12.5% during the second quarter of 2023.
During the quarter, innovations were launched in all business areas that strengthen our customer and consumer offering and reduce our environmental impact. Our two leading brands, Tork and Libresse, launched Tork Period Care dispenser, which offers feminine care products in public restrooms. We are continuing to build on our globally leading position in leakproof apparel and expanded our offering in Latin America with reusable pads under the Saba and Nosotras brands. Our sustainability work was recognized when we were once again awarded a Platinum medal by EcoVadis.
The adjusted return on capital employed increased to 13.2%. We are working in a focused manner – through innovation, value-generating customer offerings, strong brands, efficiency improvements and sustainable, profitable growth – to achieve our target of an adjusted return on capital employed of above 17% by 2025.
Magnus Groth President and CEO

| SEKm | 2306 | 2206 | % | 2023:2 | 2022:2 | % |
|---|---|---|---|---|---|---|
| Net sales | 86,856 | 72,230 | 20 | 43,930 | 37,929 | 16 |
| Cost of goods sold | -63,229 | -53,922 | -31,851 | -28,321 | ||
| Items affecting comparability - cost of goods sold | -317 | -1,466 | -355 | -383 | ||
| Gross profit | 23,310 | 16,842 | 38 | 11,724 | 9,225 | 27 |
| Adjusted gross profit1 | 23,627 | 18,308 | 29 | 12,079 | 9,608 | 26 |
| Sales, general and administration | -14,578 | -12,348 | -7,386 | -6,460 | ||
| Items affecting comparability - sales, general and administration | -82 | -205 | -131 | -125 | ||
| Share of profits of associates and joint ventures | 10 | 24 | 8 | 10 | ||
| Operating profit before amortization of acquisition-related intangible assets (EBITA) |
8,660 | 4,313 | 101 | 4,215 | 2,650 | 59 |
| Adjusted operating profit before amortization of acquisition-related intangible assets (EBITA)1 |
9,059 | 5,984 | 51 | 4,701 | 3,158 | 49 |
| Amortization of acquisition-related intangible assets | -567 | -539 | -281 | -276 | ||
| Items affecting comparability - acquisition-related intangible assets | -33 | -257 | -33 | -7 | ||
| Operating profit | 8,060 | 3,517 | 129 | 3,901 | 2,367 | 65 |
| Adjusted operating profit1 | 8,492 | 5,445 | 56 | 4,420 | 2,882 | 53 |
| Financial items | -1,288 | -432 | -633 | -224 | ||
| Profit before tax | 6,772 | 3,085 | 120 | 3,268 | 2,143 | 52 |
| Adjusted profit before tax1 | 7,204 | 5,013 | 44 | 3,787 | 2,658 | 42 |
| Income taxes | -1,518 | -891 | -717 | -470 | ||
| Profit for the period | 5,254 | 2,194 | 139 | 2,551 | 1,673 | 52 |
| Adjusted profit for the period1 | 5,536 | 4,011 | 38 | 2,914 | 2,083 | 40 |
| 1 Excluding items affecting comparability | ||||||
| Tax on amortization of acquisition-related intangible assets | 158 | 154 | 79 | 88 | ||
| Margins (%) | ||||||
| Gross margin | 26.8 | 23.3 | 26.7 | 24.3 | ||
| Adjusted gross margin1 | 27.2 | 25.3 | 27.5 | 25.3 | ||
| EBITA margin | 10.0 | 6.0 | 9.6 | 7.0 | ||
| Adjusted EBITA margin1 | 10.4 | 8.3 | 10.7 | 8.3 | ||
| Operating margin | 9.3 | 4.9 | 8.9 | 6.2 | ||
| Adjusted operating margin1 | 9.8 | 7.5 | 10.1 | 7.6 | ||
| Financial net margin | -1.5 | -0.6 | -1.4 | -0.6 | ||
| Profit margin | 7.8 | 4.3 | 7.5 | 5.6 | ||
| Adjusted profit margin1 | 8.3 | 6.9 | 8.7 | 7.0 | ||
| Income taxes | -1.7 | -1.2 | -1.6 | -1.2 | ||
| Adjusted income taxes1 | -1.9 | -1.4 | -2.0 | -1.5 | ||
| Net margin | 6.1 | 3.1 | 5.9 | 4.4 | ||
| Adjusted net margin1 | 6.4 | 5.5 | 6.7 | 5.5 |
1Excluding items affecting comparability

| SEKm | 2306 | 2206 | % | 2023:2 | 2022:2 | % |
|---|---|---|---|---|---|---|
| Health & Medical | 1,712 | 1,509 | 13 | 943 | 673 | 40 |
| Consumer Goods | 4,964 | 3,506 | 42 | 2,493 | 1,861 | 34 |
| Professional Hygiene | 2,895 | 1,479 | 96 | 1,594 | 916 | 74 |
| Other | -512 | -510 | -329 | -292 | ||
| Total1 | 9,059 | 5,984 | 51 | 4,701 | 3,158 | 49 |
1Excluding items affecting comparability; for amounts see page 13.
| SEKm | 2306 | 2206 | % | 2023:2 | 2022:2 | % |
|---|---|---|---|---|---|---|
| Health & Medical | 1,282 | 1,098 | 17 | 731 | 463 | 58 |
| Consumer Goods | 4,839 | 3,387 | 43 | 2,431 | 1,801 | 35 |
| Professional Hygiene | 2,884 | 1,470 | 96 | 1,589 | 911 | 74 |
| Other | -513 | -510 | -331 | -293 | ||
| Total1 | 8,492 | 5,445 | 56 | 4,420 | 2,882 | 53 |
1Excluding items affecting comparability; for amounts see page 13.
| SEKm | 2306 | 2206 | % | 2023:2 | 2022:2 | % |
|---|---|---|---|---|---|---|
| Health & Medical | 556 | 629 | -12 | 274 | 105 | 161 |
| Consumer Goods | 2,068 | 3,337 | -38 | 937 | 1,363 | -31 |
| Professional Hygiene | 2,722 | 870 | 213 | 1,793 | 740 | 142 |
| Other | -1,103 | -797 | -992 | -421 | ||
| Total | 4,243 | 4,039 | 5 | 2,012 | 1,787 | 13 |


Excluding items affecting comparability
| Change in net sales (%) | ||||||
|---|---|---|---|---|---|---|
| 2306 vs 2206 |
23:2 vs 22:2 |
|||||
| Total | 20.2 | 15.8 | ||||
| Volume | -3.1 | -3.6 | ||||
| Price/mix | 14.6 | 11.0 | ||||
| Currency | 7.4 | 7.1 | ||||
| Acquisitions | 1.3 | 1.3 | ||||
| Divestments | 0.0 | 0.0 |
| 2306 vs 2206 |
23:2 vs 22:2 |
|
|---|---|---|
| Total | 51 | 49 |
| Volume | -6 | -8 |
| Price/mix | 177 | 138 |
| Raw materials | -72 | -50 |
| Energy | -16 | -13 |
| Other goods sold | -28 | -21 |
| Sales & admin | -24 | -19 |
| Currency | 13 | 13 |
| Other | 7 | 9 |

Excluding items affecting comparability

Net sales increased 20.2% to SEK 86,856m (72,230). Sales growth, including organic sales growth and acquisitions, amounted to 12.8%, of which volume accounted for -3.1%, price/mix for 14.6% and acquisitions for 1.3%. Sales prices were higher and the mix better in all business areas. Volumes were negatively impacted on account of the company's prioritization of higher profitability ahead of volume. Furthermore, volumes were negatively impacted by lower volumes in Russia and the discontinuation of the baby diaper business in Latin America. Organic sales growth in mature markets amounted to 11.5% and in emerging markets to 11.6%. Emerging markets accounted for 37% of net sales. Exchange rate effects increased net sales by 7.4%.
The Group's gross margin increased to 26.8% (23.3). The Group's adjusted gross margin increased 1.9 percentage points to 27.2% (25.3). The margin was positively impacted by higher selling prices and a better mix in all business areas. Higher costs for raw materials, energy and distribution reduced the margin by 6.8 percentage points. The margin was also negatively impacted by salary inflation and lower volumes, and thus lower cost absorption.
The Group's EBITA margin increased to 10.0% (6.0). The Group's adjusted EBITA margin increased 2.1 percentage points to 10.4% (8.3). Sales costs were higher, mainly due to salary inflation and higher marketing costs in Consumer Goods. Sales costs declined as a share of net sales.
Operating profit before amortization of acquisition-related intangible assets (EBITA) increased to SEK 8,660m (4,313). Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) increased 51% (36% excluding currency translation effects, acquisitions and divestments) to SEK 9,059m (5,984).
Items affecting comparability amounted to SEK -432m (-1,928). Costs are mainly attributable to restructuring costs.
Financial items increased to SEK -1,288m (-432) on account of higher average net debt and higher interest rates.
Profit before tax increased to SEK 6,772m (3,085). Adjusted profit before tax increased 44% (30% excluding currency translation effects, acquisitions and divestments) to SEK 7,204m (5,013).
The tax expense was SEK 1,518m (891). The tax expense, excluding effects of items affecting comparability, was SEK 1,668m (1,002).
Profit for the period increased 139% (125% excluding currency translation effects, acquisitions and divestments) to SEK 5,254m (2,194). Adjusted profit for the period increased 38% (24% excluding currency translation effects, acquisitions and divestments) to SEK 5,536m (4,011).
Earnings per share increased to SEK 7.32 (2.55). Adjusted earnings per share increased to SEK 8.31 (5.69).
Return on capital employed was 10.8% (9.2). The adjusted return on capital employed was 11.4% (10.2). Return on equity was 11.7% (10.7). The adjusted return on equity was 12.6% (12.6).
Net sales increased 15.8% to SEK 43,930m (37,929). Sales growth, including organic sales growth and acquisitions, amounted to 8.7%, of which volume accounted for -3.6%, price/mix for 11.0% and acquisitions for 1.3%. Sales prices were higher and the mix better. Volumes were negatively impacted on account of the company's prioritization of higher profitability ahead of volume and restructuring measures in Professional Hygiene's European operations. Furthermore, volumes were negatively impacted by lower volumes in Russia and the discontinuation of the baby diaper business in Latin America. Organic sales growth in mature markets amounted to 6.8% and in emerging markets to 8.8%. Emerging markets accounted for 37% of net sales. Exchange rate effects increased net sales by 7.1%.
The Group's gross margin increased to 26.7% (24.3). The Group's adjusted gross margin increased 2.2 percentage points to 27.5% (25.3). The margin was positively impacted by higher

selling prices, a better mix and cost savings. Higher costs for raw materials and energy reduced the margin by 4.9 percentage points. The margin was also negatively impacted by salary inflation and lower volumes, and thus lower cost absorption.
The Group's EBITA margin increased to 9.6% (7.0). The Group's adjusted EBITA margin increased 2.4 percentage points to 10.7% (8.3). Sales costs were higher, mainly due to salary inflation and higher marketing costs in Consumer Goods. Sales costs declined as a share of net sales.
Operating profit before amortization of acquisition-related intangible assets (EBITA) increased to SEK 4,215m (2,650). Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) increased 49% (34% excluding currency translation effects, acquisitions and divestments) to SEK 4,701m (3,158).
Profit for the period increased 52% (39% excluding currency translation effects, acquisitions and divestments) to SEK 2,551m (1,673). Adjusted profit for the period increased 40% (27% excluding currency translation effects, acquisitions and divestments) to SEK 2,914m (2,083).
Earnings per share increased to SEK 3.53 (2.11). Adjusted earnings per share increased to SEK 4.33 (2.97).
Return on capital employed increased to 11.8% (8.0) and the adjusted return on capital employed to 13.2% (9.6). Return on equity increased to 13.3% (9.2). The adjusted return on equity increased to 15.2% (11.5).
The operating cash surplus amounted to SEK 13,255m (9,804). The cash flow effect of changes in working capital was SEK -4,950m (-2,237). Working capital was negatively impacted by lower trade payables on account of lower purchasing volumes and lower prices for raw materials. Credit periods in trade payables are unchanged. In addition, working capital was negatively impacted by higher trade receivables due to higher selling prices. Credit periods for trade receivables were also unchanged. Lower inventories had a positive impact on working capital. Investments in non-current assets, net, excluding investments in operating assets through leases, amounted to SEK -3,293m (-3,003). Operating cash flow before investments in operating assets through leases amounted to SEK 4,507m (4,264). Operating cash flow was SEK 4,243m (4,039).
Financial items increased to SEK -1,288m (-432) on account of higher average net debt and higher interest rates.
Tax payments had an impact on cash flow of SEK -1,704m (-1,320).
Acquisitions amounted to SEK -26m (-459). Net cash flow totaled SEK -4,096m (-3,353).
Net debt increased by SEK 6,255m during the period to SEK 69,124m. Excluding pension liabilities, net debt amounted to SEK 69,452m. Net cash flow increased net debt by SEK 4,096m. Fair value measurement of pension assets and updated assumptions and assessments that affect measurement of the net pension liability, together with fair value measurement of financial instruments, reduced net debt by SEK 1,119m. Exchange rate movements increased net debt by SEK 3,112m. The debt/equity ratio was 0.86 (0.78). Excluding pension liabilities, the debt/equity ratio was 0.87 (0.77). The debt payment capacity was 27% (27). Net debt in relation to EBITDA amounted to 2.95 (3.01). Net debt in relation to adjusted EBITDA amounted to 2.90 (3.06).
The Group's equity increased by SEK 3,512m during the period, to SEK 80,076m. Profit for the period increased equity by SEK 5,254m. Equity decreased due to dividends to shareholders of SEK 5,333m. Equity increased net after tax by SEK 844m as a result of fair value measurement of pension assets and updated assumptions and assessments that affect the valuation of the pension liability. Fair value measurement of financial instruments decreased equity by SEK 1,775m after tax. Exchange rate movements, including the effect of hedges of net foreign investments, after tax, increased equity by SEK 4,570m. Other items reduced equity by SEK 48m.

A tax expense of SEK 1,668m was reported, excluding items affecting comparability, corresponding to a tax rate of 23.2% for the period. The tax expense including items affecting comparability was SEK 1,518m, corresponding to a tax rate of 22.4% for the period.
On April 26, 2023, Essity announced that the company has decided to initiate a strategic review of the company's ownership of the Asian hygiene company Vinda International Holdings Ltd (Vinda) and the Consumer Tissue Private Label Europe business with the aim of reducing Consumer Tissue's share of the company's total sales. The strategic review includes exploring different options and may result in divestments, although no such decisions have yet been taken.
On July 17, 2023, Essity announced that it had completed the divestment of its operations in Russia for a purchase price of approximately SEK 1.2bn on a cash and debt-free basis. Essity has thus exited Russia.
Essity began work in April 2022 to exit the Russian market and in 2022 an impairment was carried out of the company's assets in Russia of approximately SEK 1.7bn.
In 2022, Essity's net sales in Russia corresponded to about 2% of its total consolidated net sales.
The buyer is the company New Technologies LLC, with the principal owner Igor Shilov. The earnings impact, including accumulated currency translation differences, amounts to approximately SEK -0.5bn and will be reported as an item affecting comparability in the third quarter of 2023.



Share of Group, adjusted EBITA 2306


0 5 10 15 20 0 250 500 750 1,000 Adjusted EBITA and margin SEKm %
| 2306 vs 2206 |
23:2 vs 22:2 |
|
|---|---|---|
| Total | 15.7 | 14.8 |
| Volume | -1.9 | -3.5 |
| Price/mix | 11.1 | 11.5 |
| Currency | 6.5 | 6.8 |
| Acquisitions | 0.0 | 0.0 |
| Divestments | 0.0 | 0.0 |
| 2306 vs 2206 |
23:2 vs 22:2 |
|
|---|---|---|
| Total | 13 | 40 |
| Volume | -5 | -13 |
| Price/mix | 84 | 97 |
| Raw materials | -42 | -46 |
| Energy | -2 | -4 |
| Other goods sold | -11 | 5 |
| Sales & admin | -18 | -12 |
| Currency | 8 | 11 |
| Other | -1 | 2 |
| SEKm | 2306 | 2206 | % | 2023:2 | 2022:2 | % |
|---|---|---|---|---|---|---|
| Net sales | 13,850 | 11,967 | 16 | 7,051 | 6,145 | 15 |
| Adjusted gross profit margin, %* | 37.8 | 38.1 | 38.5 | 36.7 | ||
| Adjusted EBITA* | 1,712 | 1,509 | 13 | 943 | 673 | 40 |
| Adjusted EBITA margin, %* | 12.4 | 12.6 | 13.4 | 11.0 | ||
| Adjusted operating profit* | 1,282 | 1,098 | 17 | 731 | 463 | 58 |
| Adjusted operating margin, %* | 9.3 | 9.2 | 10.4 | 7.5 | ||
| Adjusted return on capital employed, %* | 8.8 | 10.9 | 10.5 | 8.0 | ||
| Operating cash flow | 556 | 629 | 274 | 105 |
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales increased 15.7% to SEK 13,850m (11,967). Sales growth, including organic sales growth and acquisitions, amounted to 9.2%, of which volume accounted for -1.9%, price/mix for 11.1% and acquisitions for 0.0%. The organic sales growth amounted to 8.4% in mature markets. In emerging markets, which accounted for 20% of net sales, organic sales growth was 12.3%. Exchange rate effects increased net sales by 6.5%.
For Incontinence Products Health Care, with Essity's globally leading TENA brand, organic sales growth amounted to 10.4% due to higher prices and a better mix. Volumes decreased somewhat as a result of the decision to exit contracts with insufficient profitability and lower volumes in Russia. In Medical Solutions, organic sales growth amounted to 7.5% as a result of higher prices and a better mix.
The adjusted gross margin decreased 0.3 percentage points to 37.8% (38.1). Higher costs for raw materials and energy, lower volumes and salary inflation had a negative impact on the margin. The margin was positively impacted by higher prices and a better mix. The adjusted EBITA margin decreased 0.2 percentage points to 12.4% (12.6). Sales costs were higher, mainly due to salary inflation. Sales costs were unchanged as a share of net sales. Adjusted EBITA increased 13% (5% excluding currency translation effects, acquisitions and divestments) to SEK 1,712m (1,509).
The operating cash surplus amounted to SEK 2,186m (1,935).
Net sales increased 14.8% to SEK 7,051m (6,145). Sales growth, including organic sales growth and acquisitions, amounted to 8.0%, of which volume accounted for -3.5%, price/mix for 11.5% and acquisitions for 0.0%. The organic sales growth amounted to 7.1% in mature markets. In emerging markets, which accounted for 21% of net sales, organic sales growth was 11.4%. Exchange rate effects increased net sales by 6.8%.
For Incontinence Products Health Care, with Essity's globally leading TENA brand, organic sales growth amounted to 10.1% due to higher prices and a better mix. Volumes decreased as a result of the decision to discontinue contracts with insufficient profitability. In Medical Solutions, organic sales growth amounted to 5.1% mainly as a result of higher prices. Sales growth was high in the Compression Therapy product segment.
-6 The adjusted gross margin increased 1.8 percentage points to 38.5% (36.7). The margin was positively impacted by higher prices, a better mix and cost savings. Higher costs for raw materials and energy, lower volumes and salary inflation had a negative impact on the margin. The adjusted EBITA margin increased 2.4 percentage points to 13.4% (11.0). Sales costs increased primarily due to salary inflation and somewhat higher marketing costs. Sales costs declined as a share of net sales. Adjusted EBITA increased 40% (29% excluding currency translation effects, acquisitions and divestments) to SEK 943m (673).


| SEKm | 2306 | 2206 | % | 2023:2 | 2022:2 | % |
|---|---|---|---|---|---|---|
| Net sales | 52,653 | 43,956 | 20 | 26,344 | 22,970 | 15 |
| Adjusted gross profit margin, %* | 24.6 | 23.1 | 24.6 | 23.2 | ||
| Adjusted EBITA* | 4,964 | 3,506 | 42 | 2,493 | 1,861 | 34 |
| Adjusted EBITA margin, %* | 9.4 | 8.0 | 9.5 | 8.1 | ||
| Adjusted operating profit* | 4,839 | 3,387 | 43 | 2,431 | 1,801 | 35 |
| Adjusted operating margin, %* | 9.2 | 7.7 | 9.2 | 7.8 | ||
| Adjusted return on capital employed, %* | 11.1 | 10.4 | 12.5 | 10.5 | ||
| Operating cash flow | 2,068 | 3,337 | 937 | 1,363 |
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales increased 19.8% to SEK 52,653m (43,956). Sales growth, including organic sales growth and acquisitions, amounted to 12.6%, of which volume accounted for -3.1%, price/mix for 13.6% and acquisitions for 2.1%. Volumes declined on account of the company's prioritization of higher profitability ahead of volume. In addition, volumes were negatively impacted by lower volumes in Russia. Organic sales growth amounted to 9.8% in mature markets. In emerging markets, which accounted for 49% of net sales, organic sales growth was 11.2%. Exchange rate effects increased net sales by 7.2%.
The adjusted gross margin increased 1.5 percentage points to 24.6% (23.1). The margin was positively impacted by higher prices and a better mix. Higher costs for raw materials, energy and distribution, lower volumes and salary inflation, had a negative impact on the margin. The adjusted EBITA margin increased 1.4 percentage points to 9.4% (8.0). Sales costs were higher due to salary inflation and higher marketing costs. Sales costs were unchanged as a share of net sales. Adjusted EBITA increased 42% (26% excluding currency translation effects, acquisitions and divestments) to SEK 4,964m (3,506).
The operating cash surplus amounted to SEK 7,311m (5,625).
Net sales increased 14.7% to SEK 26,344m (22,970). Sales growth, including organic sales growth and acquisitions, amounted to 8.0%, of which volume accounted for -3.0%, price/mix for 8.8% and acquisitions for 2.2%. Sales prices were higher in all product segments. Volumes declined on account of the company's prioritization of higher profitability ahead of volume. Organic sales growth amounted to 3.7% in mature markets. In emerging markets, which accounted for 49% of net sales, organic sales growth was 7.8%. Exchange rate effects increased net sales by 6.7%.
-6 For Incontinence Products Retail, with Essity's globally leading TENA brand, organic sales growth amounted to 13.7% due to higher volumes, higher prices and a better mix. In Feminine Care, organic sales growth amounted to 10.5% as a result of higher volumes and higher prices. In Baby Care, organic sales growth was -1.8%, mainly due to lower volumes, which were negatively impacted by the discontinuation of the baby diaper business in Latin America and the decision to exit retailer brands contract with insufficient profitability in Europe. Sales prices in Baby Care were higher. In Consumer Tissue, organic sales growth amounted to 4.8%, mainly as a result of higher prices in addition to a better mix. Volumes were lower on account of the prioritization of higher profitability ahead of volume. For the Consumer Tissue Private Label Europe division, organic sales growth amounted to 3.5% as a result of higher prices and lower volumes.
The adjusted gross margin increased 1.4 percentage points to 24.6% (23.2). The margin was positively impacted by higher prices, a better mix and cost savings. Higher costs for raw materials and energy, lower volumes and salary inflation had a negative impact on the margin. The adjusted EBITA margin increased 1.4 percentage points to 9.5% (8.1). Sales costs were higher due to salary inflation and higher marketing costs. Sales costs were somewhat lower as a share of net sales. Adjusted EBITA increased 34% (20% excluding currency translation effects, acquisitions and divestments) to SEK 2,493m (1,861).

Share of Group, adjusted EBITA 2306


Change in net sales (%)
| 2306 vs 2206 |
23:2 vs 22:2 |
|
|---|---|---|
| Total | 19.8 | 14.7 |
| Volume | -3.1 | -3.0 |
| Price/mix | 13.6 | 8.8 |
| Currency | 7.2 | 6.7 |
| Acquisitions | 2.1 | 2.2 |
| Divestments | 0.0 | 0.0 |
| 2306 vs 2206 |
23:2 vs 22:2 |
|
|---|---|---|
| Total | 42 | 34 |
| Volume | -3 | -3 |
| Price/mix | 175 | 121 |
| Raw materials | -89 | -58 |
| Energy | -18 | -16 |
| Other goods sold | -24 | -19 |
| Sales & admin | -23 | -18 |
| Currency | 12 | 11 |
| Other | 12 | 16 |





Change in net sales (%)
| 2306 vs 2206 |
23:2 vs 22:2 |
||
|---|---|---|---|
| Total | 24.8 | 19.6 | |
| Volume | -4.2 | -5.0 | |
| Price/mix | 19.9 | 16.2 | |
| Currency | 8.9 | 8.4 | |
| Acquisitions | 0.2 | 0.0 | |
| Divestments | 0.0 | 0.0 |
| 2306 vs 2206 |
23:2 vs 22:2 |
|
|---|---|---|
| Total | 96 | 74 |
| Volume | -10 | -11 |
| Price/mix | 216 | 158 |
| Raw materials | -39 | -20 |
| Energy | -20 | -12 |
| Other goods sold | -42 | -33 |
| Sales & admin | -23 | -18 |
| Currency | 13 | 10 |
| Other | 1 | 0 |
| SEKm | 2306 | 2206 | % | 2023:2 | 2022:2 | % |
|---|---|---|---|---|---|---|
| Net sales | 20,349 | 16,304 | 25 | 10,539 | 8,811 | 20 |
| Adjusted gross profit margin, %* | 26.7 | 21.7 | 27.5 | 22.5 | ||
| Adjusted EBITA* | 2,895 | 1,479 | 96 | 1,594 | 916 | 74 |
| Adjusted EBITA margin, %* | 14.2 | 9.1 | 15.1 | 10.4 | ||
| Adjusted operating profit* | 2,884 | 1,470 | 96 | 1,589 | 911 | 74 |
| Adjusted operating margin, %* | 14.2 | 9.0 | 15.1 | 10.3 | ||
| Adjusted return on capital employed, %* | 18.9 | 12.1 | 22.7 | 13.3 | ||
| Operating cash flow | 2,722 | 870 | 1,793 | 740 |
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales increased 24.8% to SEK 20,349m (16,304). Sales growth, including organic sales growth and acquisitions, amounted to 15.9%, of which volume accounted for -4.2%, price/mix for 19.9% and acquisitions for 0.2%. Volumes declined on account of the company's prioritization of higher profitability ahead of volume and restructuring measures in the European operation. In addition, volumes were negatively impacted by lower volumes in Russia. Organic sales growth amounted to 16.8% in mature markets. In emerging markets, which accounted for 18% of net sales, organic sales growth was 14.4%. Exchange rate effects increased net sales by 8.9%.
The adjusted gross margin increased by 5.0 percentage points to 26.7% (21.7). The margin was positively impacted by higher prices and a better mix. Higher costs for raw materials and energy, lower volumes and salary inflation had a negative impact on the margin. The adjusted EBITA margin increased 5.1 percentage points to 14.2% (9.1). Sales costs were higher due to salary inflation and somewhat higher marketing costs. Sales costs declined slightly as a share of net sales. Adjusted EBITA increased 96% (82% excluding currency translation effects, acquisitions and divestments) to SEK 2,895m (1,479).
The operating cash surplus amounted to SEK 4,141m (2,632).
Net sales increased 19.6% to SEK 10,539m (8,811). Sales growth, including organic sales growth and acquisitions, amounted to 11.2%, of which volume accounted for -5.0%, price/mix for 16.2% and acquisitions for 0.0%. Volumes declined on account of the company's prioritization of higher profitability ahead of volume and restructuring measures in the European operation. Organic sales growth amounted to 11.7% in mature markets. In emerging markets, which accounted for 19% of net sales, organic sales growth was 13.9%. Exchange rate effects increased net sales by 8.4%.
The adjusted gross margin increased by 5.0 percentage points to 27.5% (22.5). The margin was positively impacted by higher prices and a better mix. Higher costs for raw materials and energy, lower volumes and salary inflation had a negative impact on the margin.The adjusted EBITA margin increased 4.7 percentage points to 15.1% (10.4). Sales costs were higher due to salary inflation and somewhat higher marketing costs. Sales costs increased as a share of net sales. Adjusted EBITA increased 74% (64% excluding currency translation effects, acquisitions and divestments) to SEK 1,594m (916).
-6 Essity is continuing to improve profitability by focusing production and sales on the company's more innovative and value-creating customer offerings. As part of this process, Essity is planning to implement restructuring measures in Professional Hygiene in the US that include the closure of two production plants in New York state. Restructuring costs are estimated to amount to approximately SEK 1.2bn and will be recognized as an item affecting comparability in the third quarter of 2023. Of these costs, approximately SEK 350m is expected to impact cash flow. The restructuring measures are expected to have a low single-digit negative impact on volume in the second half of 2023 and full-year 2024.
The Board of Directors and President certify that the interim report gives a true and fair view of the Parent Company's and Group's operations, financial position and results of operations, and describes material risks and uncertainties facing the Parent Company and the companies included in the Group.
Stockholm, July 20, 2023
Essity Aktiebolag (publ)

employee representative
Board member
We have reviewed the condensed interim report for Essity Aktiebolag (publ) as at June 30, 2023 and for the six-month period then ended. The Board of Directors and the President are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.
We conducted our review in accordance with the International Standard on Review Engagements, ISRE 2410 Review of Interim Financial Statements Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and other generally accepted auditing standards in Sweden.
The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act regarding the Group, and in accordance with the Swedish Annual Accounts Act regarding the Parent Company.
Stockholm, July 20, 2023
Ernst & Young AB
Erik Sandström Authorized Public Accountant

| June 30, 2023 | Class A | Class B | Total |
|---|---|---|---|
| Registered number of shares | 61,158,914 | 641,183,575 | 702,342,489 |
At the end of the period, the proportion of Class A shares was 8.7%. In the second quarter, no Class A shares were converted to Class B shares. The total number of votes in the company amounts to 1,252,772,715.
In 2023, an interim report will be published on October 26. The year-end report for 2023 will be published on January 25, 2024.
In conjunction with publication, a telephone and web presentation will be held at 09:00 CET, where President and CEO Magnus Groth will present and answer questions.
Date: Thursday, 20 July 2023 Time: 09:00 CET Link to web presentation:https://essity.videosync.fi/2023-07-20-q2 Telephone: UK: +44 (0) 33 0551 02 00, USA: +1 786 697 35 01, SWE: +46 (0) 8 505 204 24. Please call in well in advance of the start of the presentation. Indicate: "Essity".
Fredrik Rystedt, CFO and Executive Vice President, +46 (0) 8 788 51 31 Johan Karlsson, Vice President Investor Relations, Group Function Finance, +46 (0) 70 511 15 81 Per Lorentz, Vice President Corporate Communications, Group Function Communications, +46 (0) 73 313 30 55
NB:
This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of Karl Stoltz, Media Relations Director, at 07:00 CET on July 20, 2023.

| SEKm | 2023:2 | 2022:2 | 2023:1 | 2306 | 2206 |
|---|---|---|---|---|---|
| Net sales | 43,930 | 37,929 | 42,926 | 86,856 | 72,230 |
| Cost of goods sold1,2 | -31,851 | -28,321 | -31,378 | -63,229 | -53,922 |
| Items affecting comparability - cost of goods sold2 | -355 | -383 | 38 | -317 | -1,466 |
| Gross profit | 11,724 | 9,225 | 11,586 | 23,310 | 16,842 |
| Sales, general and administration1,2 | -7,386 | -6,460 | -7,192 | -14,578 | -12,348 |
| Items affecting comparability - sales, general and administration2 | -131 | -125 | 49 | -82 | -205 |
| Share of profits of associates and joint ventures | 8 | 10 | 2 | 10 | 24 |
| Operating profit before amortization of acquisition-related intangible assets (EBITA) |
4,215 | 2,650 | 4,445 | 8,660 | 4,313 |
| Amortization of acquisition-related intangible assets | -281 | -276 | -286 | -567 | -539 |
| Items affecting comparability - acquisition-related intangible assets2 | -33 | -7 | 0 | -33 | -257 |
| Operating profit | 3,901 | 2,367 | 4,159 | 8,060 | 3,517 |
| Financial items | -633 | -224 | -655 | -1,288 | -432 |
| Profit before tax | 3,268 | 2,143 | 3,504 | 6,772 | 3,085 |
| Income taxes | -717 | -470 | -801 | -1,518 | -891 |
| Profit for the period | 2,551 | 1,673 | 2,703 | 5,254 | 2,194 |
| Earnings attributable to: | |||||
| Owners of the Parent company | 2,479 | 1,485 | 2,663 | 5,142 | 1,791 |
| Non-controlling interests | 72 | 188 | 40 | 112 | 403 |
| Earnings per share - owners of the Parent company | |||||
| Earnings per share before and after dilution effects, SEK | 3.53 | 2.11 | 3.79 | 7.32 | 2.55 |
| Average numbers of shares before and after dilution, million | 702.3 | 702.3 | 702.3 | 702.3 | 702.3 |
| 1Of which, depreciation and amortization | -2,228 | -2,068 | -2,194 | -4,422 | -4,055 |
| 2Of which, impairment | -154 | -308 | 27 | -127 | -1,690 |
| Gross margin | 26.7 | 24.3 | 27.0 | 26.8 | 23.3 |
| EBITA margin | 9.6 | 7.0 | 10.4 | 10.0 | 6.0 |
| Operating margin | 8.9 | 6.2 | 9.7 | 9.3 | 4.9 |
| Financial net margin | -1.4 | -0.6 | -1.5 | -1.5 | -0.6 |
| Profit margin | 7.5 | 5.6 | 8.2 | 7.8 | 4.3 |
| Income taxes | -1.6 | -1.2 | -1.9 | -1.7 | -1.2 |
| Net margin | 5.9 | 4.4 | 6.3 | 6.1 | 3.1 |
| Excluding items affecting comparability: | |||||
| Gross margin | 27.5 | 25.3 | 26.9 | 27.2 | 25.3 |
| EBITA margin | 10.7 | 8.3 | 10.2 | 10.4 | 8.3 |
| Operating margin | 10.1 | 7.6 | 9.5 | 9.8 | 7.5 |
| Financial net margin | -1.4 | -0.6 | -1.5 | -1.5 | -0.6 |
| Profit margin | 8.7 | 7.0 | 8.0 | 8.3 | 6.9 |
| Income taxes | -2.0 | -1.5 | -1.9 | -1.9 | -1.4 |
| Net margin | 6.7 | 5.5 | 6.1 | 6.4 | 5.5 |

| SEKm | 2023:2 | 2022:2 | 2023:1 | 2306 | 2206 |
|---|---|---|---|---|---|
| Profit for the period | 2,551 | 1,673 | 2,703 | 5,254 | 2,194 |
| Other comprehensive income for the period | |||||
| Items that will not be reclassified to the income statement | |||||
| Actuarial gains/losses on defined benefit pension plans | 651 | 934 | 466 | 1,117 | 2,262 |
| Fair value through other comprehensive income | 1 | -7 | 1 | 2 | -14 |
| Income tax attributable to components in other comprehensive income | -152 | -241 | -120 | -272 | -557 |
| 500 | 686 | 347 | 847 | 1,691 | |
| Items that have been or may be reclassified subsequently to the income statement | |||||
| Cash flow hedges | |||||
| Result from remeasurement of derivatives recognized in equity | -696 | 2,304 | -2,127 | -2,823 | 5,695 |
| Transferred to profit or loss for the period | 643 | -1,145 | -212 | 431 | -2,223 |
| Translation differences in foreign operations | 4,197 | 5,373 | 770 | 4,967 | 7,575 |
| Gains/losses from hedges of net investments in foreign operations | -690 | -1,010 | 138 | -552 | -1,378 |
| Income tax attributable to components in other comprehensive income | 155 | -121 | 600 | 755 | -664 |
| 3,609 | 5,401 | -831 | 2,778 | 9,005 | |
| Other comprehensive income for the period, net of tax | 4,109 | 6,087 | -484 | 3,625 | 10,696 |
| Total comprehensive income for the period | 6,660 | 7,760 | 2,219 | 8,879 | 12,890 |
| Total comprehensive income attributable to: | |||||
| Owners of the Parent company | 6,674 | 7,193 | 2,125 | 8,799 | 11,847 |
| Non-controlling interests | -14 | 567 | 94 | 80 | 1,043 |
| SEKm | 2306 | 2206 |
|---|---|---|
| Equity attributable to owners of the Parent company | ||
| Value, January 1 | 67,346 | 59,874 |
| Total comprehensive income for the period | 8,799 | 11,847 |
| Dividend | -5,092 | -4,916 |
| Acquisition of non-controlling interests | 1 | -9 |
| Private placement to non-controlling interests | 0 | 17 |
| Transferred to cost of hedged investments | 13 | 18 |
| Revaluation effect upon acquisition of non-controlling interests | -48 | 0 |
| Value, June 30 | 71,019 | 66,831 |
| Non-controlling interests | ||
| Value, January 1 | 9,218 | 8,633 |
| Total comprehensive income for the period | 80 | 1,043 |
| Dividend | -241 | -312 |
| Private placement to non-controlling interests | 0 | 16 |
| Acquisition of non-controlling interests | 0 | -4 |
| Value, June 30 | 9,057 | 9,376 |
| Total equity, value June 30 | 80,076 | 76,207 |

| SEKm | 2306 | 2206 |
|---|---|---|
| Operating activities | ||
| Operating profit | 8,060 | 3,517 |
| Adjustment for non-cash items1 | 5,099 | 6,250 |
| Interest paid | -804 | -419 |
| Interest received | 155 | 54 |
| Other financial items | -651 | -148 |
| Capitalized expenditures to fulfill contracts with customers | -237 | -226 |
| Change in liabilities relating to restructuring programs, etc. | -159 | -29 |
| Paid tax | -1,704 | -1,320 |
| Cash flow from operating activities before | ||
| changes in working capital | 9,759 | 7,679 |
| Cash flow from changes in working capital | ||
| Change in inventories | 2,095 | -2,251 |
| Change in operating receivables | -1,717 | -3,182 |
| Change in operating liabilities | -5,328 | 3,196 |
| Cash flow from operating activities | 4,809 | 5,442 |
| Investing activities | ||
| Acquisitions of Group companies and other operations | -10 | -357 |
| Investments in intangible assets and property, plant and equipment | -3,303 | -3,026 |
| Sale of property, plant and equipment | 19 | 50 |
| Investments in financial assets, etc. | -565 | -2,126 |
| Paid interest capitalized in intangible assets and property, plant and equipment | -9 | -27 |
| Cash flow from investing activities | -3,868 | -5,486 |
| Financing activities | ||
| Private placement to non-controlling interests | 0 | 34 |
| Acquisition of non-controlling interests | 0 | -13 |
| Dividend | -5,092 | -4,916 |
| Proceeds from borrowings | 10,395 | 11,529 |
| Repayment of borrowings | -3,733 | -5,740 |
| Dividend to non-controlling interests | -242 | -307 |
| Cash flow from financing activities | 1,328 | 587 |
| Cash flow for the period | 2,269 | 543 |
| Cash and cash equivalents at the beginning of the period | 4,288 | 3,904 |
| Translation differences in cash and cash equivalents | -44 | 548 |
| Cash and cash equivalents at the end of the period | 6,513 | 4,995 |
| Cash flow from operating activities per share, SEK | 6.85 | 7.75 |
| Reconciliation with consolidated operating cash flow statement | ||
| Cash flow for the period | 2,269 | 543 |
| Repayment of borrowings | 3,733 | 5,740 |
| Proceeds from borrowings | -10,395 | -11,529 |
| Investments in financial assets, etc. | 565 | 2,126 |
| Investments in operating assets through leases | -264 | -225 |
| Net debt in acquired and divested operations Accrued interest |
-16 12 |
-89 81 |
| Net cash flow according to consolidated operating cash flow statement | -4,096 | -3,353 |
| 1) Adjustment for non-cash items | ||
| Depreciation/amortization and impairment of non-current assets | 4,549 | 5,745 |
| Gain/loss on sale of assets | 4 | 1 |
| Depreciation of prepaid selling expenses | 244 | 221 |
| Gain/loss on divestment and liquidation | 0 | 2 |
| Non-cash items relating to efficiency program | 217 | 115 |
| Other | 85 | 166 |
| Total | 5,099 | 6,250 |

| SEKm | 2306 | 2206 |
|---|---|---|
| Operating cash surplus | 13,255 | 9,804 |
| Change in working capital | -4,950 | -2,237 |
| Investments in non-current assets, net | -3,293 | -3,003 |
| Restructuring costs, etc. | -505 | -300 |
| Operating cash flow before Investments in operating assets through leases | 4,507 | 4,264 |
| Investments in operating assets through leases | -264 | -225 |
| Operating cash flow | 4,243 | 4,039 |
| Financial items | -1,288 | -432 |
| Income taxes paid | -1,704 | -1,320 |
| Other | 13 | 8 |
| Cash flow from current operations | 1,264 | 2,295 |
| Acquisitions of Group companies and other operations | -26 | -459 |
| Cash flow before transactions with shareholders | 1,238 | 1,836 |
| Private placement to non-controlling interest | 0 | 34 |
| Dividend to non-controlling interests | -242 | -307 |
| Dividend | -5,092 | -4,916 |
| Net cash flow | -4,096 | -3,353 |
| Net debt at the beginning of the period | -62,869 | -55,433 |
| Net cash flow | -4,096 | -3,353 |
| Remeasurements to equity | 1,119 | 2,248 |
| Investments in non-operating assets through leases | -166 | -276 |
| Translation differences | -3,112 | -2,845 |
| Net debt at the end of the period | -69,124 | -59,659 |
| Debt/equity ratio | 0.86 | 0.78 |
| Debt payment capacity, % | 27 | 27 |
| Net debt / EBITDA | 2.95 | 3.01 |
| Net debt / Adjusted EBITDA | 2.90 | 3.06 |

| SEKm | June 30, 2023 | December 31, 2022 |
|---|---|---|
| ASSETS | ||
| Non-current assets | ||
| Goodwill | 47,005 | 44,786 |
| Other intangible assets | 26,202 | 25,346 |
| Property, plant and equipment | 66,054 | 62,898 |
| Investments in associates and joint ventures | 302 | 291 |
| Shares and participations | 6 | 6 |
| Surplus in funded pension plans | 2,845 | 1,965 |
| Non-current financial assets | 140 | 123 |
| Deferred tax assets | 3,032 | 2,545 |
| Other non-current assets | 952 | 1,620 |
| Total non-current assets | 146,538 | 139,580 |
| Current Assets | ||
| Inventories | 28,027 | 28,888 |
| Trade receivables | 28,444 | 25,990 |
| Current tax assets | 1,064 | 1,152 |
| Other current receivables | 5,152 | 5,761 |
| Current financial assets | 5,865 | 4,941 |
| Cash and cash equivalents | 6,513 | 4,288 |
| Total current assets | 75,065 | 71,020 |
| Total assets | 221,603 | 210,600 |
| EQUITY AND LIABILITIES | ||
| Equity | ||
| Share capital | 2,350 | 2,350 |
| Reserves | 14,299 | 11,477 |
| Retained earnings | 54,370 | 53,519 |
| Attributable to owner of the Parent | 71,019 | 67,346 |
| Non-controlling interests | 9,057 | 9,218 |
| Total equity | 80,076 | 76,564 |
| Non-current liabilities | ||
| Non-current financial liabilities | 56,054 | 58,242 |
| Provisions for pensions | 2,517 | 2,671 |
| Deferred tax liabilities | 8,570 | 8,718 |
| Other non-current provisions | 374 | 491 |
| Other non-current liabilities | 1,336 | 1,196 |
| Total non-current liabilities | 68,851 | 71,318 |
| Current liabilities | ||
| Current financial liabilities | 25,916 | 13,273 |
| Trade payables | 21,760 | 25,644 |
| Current tax liabilities | 1,593 | 1,589 |
| Current provisions | 953 | 1,217 |
| Other current liabilities | 22,454 | 20,995 |
| Total current liabilities | 72,676 | 62,718 |
| Total liabilities | 141,527 | 134,036 |
| Total equity and liabilities | 221,603 | 210,600 |

| SEKm | June 30, 2023 | December 31, 2022 |
|---|---|---|
| Debt/equity ratio | 0.86 | 0.82 |
| Equity/assets ratio | 32% | 32% |
| Equity | 80,076 | 76,564 |
| Equity per share, SEK | 114 | 109 |
| Return on equity | 11.7% | 8.1% |
| Return on equity, excluding items affecting comparability | 12.6% | 11.1% |
| Capital employed | 149,200 | 139,433 |
| - of which working capital | 18,124 | 14,033 |
| Return on capital employed* | 10.8% | 8.1% |
| Return on capital employed*, excluding items affecting comparability | 11.4% | 9.7% |
| Net debt | 69,124 | 62,869 |
| Provisions for restructuring costs are included in the balance sheet as follows | ||
| -Other non-current provisions | 107 | 105 |
| -Other current provisions | 417 | 213 |
*) rolling 12 months

| SEKm | 2306 | 2206 | 2023:2 | 2023:1 | 2022:4 | 2022:3 | 2022:2 | 2022:1 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 13,850 | 11,967 | 7,051 | 6,799 | 6,728 | 6,544 | 6,145 | 5,822 |
| Consumer Goods | 52,653 | 43,956 | 26,344 | 26,309 | 27,060 | 23,825 | 22,970 | 20,986 |
| Professional Hygiene | 20,349 | 16,304 | 10,539 | 9,810 | 10,077 | 9,733 | 8,811 | 7,493 |
| Other | 4 | 3 | -4 | 8 | -31 | 7 | 3 | 0 |
| Total | 86,856 | 72,230 | 43,930 | 42,926 | 43,834 | 40,109 | 37,929 | 34,301 |
| (%) | 2306 | 2206 | 2023:2 | 2023:1 | 2022:4 | 2022:3 | 2022:2 | 2022:1 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 9.2 | 8.6 | 8.0 | 10.5 | 4.6 | 7.6 | 7.9 | 9.5 |
| Consumer Goods | 10.5 | 14.7 | 5.8 | 15.7 | 15.7 | 17.6 | 17.9 | 11.5 |
| Professional Hygiene | 15.7 | 27.8 | 11.2 | 21.0 | 18.3 | 19.9 | 26.1 | 29.8 |
| Total | 11.5 | 16.3 | 7.4 | 16.0 | 14.3 | 16.3 | 17.8 | 14.6 |
| (%) | 2306 | 2206 | 2023:2 | 2023:1 | 2022:4 | 2022:3 | 2022:2 | 2022:1 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 9.2 | 11.3 | 8.0 | 10.5 | 6.3 | 9.9 | 10.9 | 11.7 |
| Consumer Goods | 12.6 | 16.9 | 8.0 | 17.6 | 17.8 | 18.4 | 20.0 | 13.8 |
| Professional Hygiene | 15.9 | 32.0 | 11.2 | 21.3 | 18.8 | 20.3 | 30.2 | 34.1 |
| Total | 12.8 | 19.0 | 8.7 | 17.2 | 16.0 | 17.3 | 20.6 | 17.3 |
| SEKm | 2306 | 2206 | 2023:2 | 2023:1 | 2022:4 | 2022:3 | 2022:2 | 2022:1 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 1,712 | 1,509 | 943 | 769 | 721 | 673 | 673 | 836 |
| Consumer Goods | 4,964 | 3,506 | 2,493 | 2,471 | 2,245 | 1,460 | 1,861 | 1,645 |
| Professional Hygiene | 2,895 | 1,479 | 1,594 | 1,301 | 1,423 | 1,096 | 916 | 563 |
| Other | -512 | -510 | -329 | -183 | -305 | -239 | -292 | -218 |
| Total | 9,059 | 5,984 | 4,701 | 4,358 | 4,084 | 2,990 | 3,158 | 2,826 |
| SEKm | 2306 | 2206 | 2023:2 | 2023:1 | 2022:4 | 2022:3 | 2022:2 | 2022:1 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 1,282 | 1,098 | 731 | 551 | 500 | 456 | 463 | 635 |
| Consumer Goods | 4,839 | 3,387 | 2,431 | 2,408 | 2,182 | 1,395 | 1,801 | 1,586 |
| Professional Hygiene | 2,884 | 1,470 | 1,589 | 1,295 | 1,417 | 1,091 | 911 | 559 |
| Other | -513 | -510 | -331 | -182 | -305 | -239 | -293 | -217 |
| Total adjusted operating profit1 | 8,492 | 5,445 | 4,420 | 4,072 | 3,794 | 2,703 | 2,882 | 2,563 |
| Financial items | -1,288 | -432 | -633 | -655 | -570 | -368 | -224 | -208 |
| Profit before tax1 | 7,204 | 5,013 | 3,787 | 3,417 | 3,224 | 2,335 | 2,658 | 2,355 |
| Income taxes | -1,668 | -1,002 | -873 | -795 | -734 | -509 | -575 | -427 |
| Net profit for the period2 | 5,536 | 4,011 | 2,914 | 2,622 | 2,490 | 1,826 | 2,083 | 1,928 |
| 1Excluding items affecting comparability before tax amounting to: | -432 | -1,928 | -519 | 87 | -323 | -212 | -515 | -1,413 |
| 2Excluding items affecting comparability after tax amounting to: | -282 | -1,817 | -363 | 81 | -244 | -202 | -410 | -1,407 |
| (%) | 2306 | 2206 | 2023:2 | 2023:1 | 2022:4 | 2022:3 | 2022:2 | 2022:1 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 12.4 | 12.6 | 13.4 | 11.3 | 10.7 | 10.3 | 11.0 | 14.4 |
| Consumer Goods | 9.4 | 8.0 | 9.5 | 9.4 | 8.3 | 6.1 | 8.1 | 7.8 |
| Professional Hygiene | 14.2 | 9.1 | 15.1 | 13.3 | 14.1 | 11.3 | 10.4 | 7.5 |
| Total | 10.4 | 8.3 | 10.7 | 10.2 | 9.3 | 7.5 | 8.3 | 8.2 |

| SEKm | 2023:2 | 2023:1 | 2022:4 | 2022:3 | 2022:2 |
|---|---|---|---|---|---|
| Net sales | 43,930 | 42,926 | 43,834 | 40,109 | 37,929 |
| Cost of goods sold | -31,851 | -31,378 | -32,499 | -30,625 | -28,321 |
| Items affecting comparability - cost of goods sold | -355 | 38 | -302 | -131 | -383 |
| Gross profit | 11,724 | 11,586 | 11,033 | 9,353 | 9,225 |
| Sales, general and administration | -7,386 | -7,192 | -7,259 | -6,500 | -6,460 |
| Items affecting comparability - sales, general and administration | -131 | 49 | 8 | -75 | -125 |
| Share of results of associates and joint ventures | 8 | 2 | 8 | 6 | 10 |
| EBITA | 4,215 | 4,445 | 3,790 | 2,784 | 2,650 |
| Amortization of acquisition-related intangible assets | -281 | -286 | -290 | -287 | -276 |
| Items affecting comparability - acquisition-related intangible assets | -33 | 0 | -29 | -6 | -7 |
| Operating profit | 3,901 | 4,159 | 3,471 | 2,491 | 2,367 |
| Financial items | -633 | -655 | -570 | -368 | -224 |
| Profit before tax | 3268 | 3,504 | 2,901 | 2,123 | 2,143 |
| Income taxes | -717 | -801 | -655 | -499 | -470 |
| Net profit for the period | 2,551 | 2,703 | 2,246 | 1,624 | 1,673 |
| SEKm | 2306 | 2206 |
|---|---|---|
| Administrative expenses | -432 | -380 |
| Other operating income | 25 | 22 |
| Operating loss | -407 | -358 |
| Financial items | 1,341 | 214 |
| Profit before tax | 934 | -144 |
| Tax on profit for the period | 71 | 435 |
| Profit for the period | 1,005 | 291 |
| SEKm | June 30, 2023 | December 31, 2022 |
|---|---|---|
| Intangible assets | 0 | 0 |
| Property, plant and equipment | 11 | 12 |
| Financial non-current assets | 176,746 | 176,780 |
| Total non-current assets | 176,757 | 176,792 |
| Total current assets | 2,388 | 3,046 |
| Total assets | 179,145 | 179,838 |
| Restricted equity | 2,350 | 2,350 |
| Non-restricted equity | 72,159 | 76,246 |
| Total equity | 74,509 | 78,596 |
| Untaxed reserves | 195 | 195 |
| Provisions | 867 | 846 |
| Non-current liabilities | 48,321 | 52,470 |
| Current liabilities | 55,253 | 47,731 |
| Total equity, provisions and liabilities | 179,145 | 179,838 |

This half-year report has been prepared in accordance with IAS 34 and recommendation RFR 1 of the Swedish Financial Reporting Board (RFR), and with regards to the Parent company, RFR 2. A few amended accounting standards published by the IASB entered into force on January 1, 2023 following approval by the EU. Essity Aktiebolag (publ) applies these amendments, which have not had any material impact on the Group's or the Parent company's financial statements. All other applied accounting principles and calculation methods correspond to those presented in Essity Aktiebolag's (publ) Annual and Sustainability Report for 2022.
Essity's Board determines the Group's strategic direction based on recommendations from the Executive Management Team. Responsibility for the long-term, overall management of strategic risks corresponds to the company's delegation structure, from the Board of Directors to the CEO and from the CEO to the Business Unit Presidents. This means that most operational risks are managed by Essity's business units at the local level, but that they are coordinated when considered necessary. The tools used in this coordination consist primarily of the business units' regular reporting and the annual strategy process, where risks and risk management are a part of the process.
Essity's financial risk management is centralized, as is the Group's internal bank for the Group companies' financial transactions and management of the Group's energy risks. Financial risks are managed in accordance with the Group's Finance Policy, which is adopted by Essity's Board of Directors and which – together with Essity's Energy Risk Policy – makes up a framework for risk management. Risks are aggregated and monitored on a regular basis to ensure compliance with these guidelines. Essity has also centralized other risk management.
Essity has a staff function for internal audit, which monitors compliance with the Group's policies in the organization.
Essity's risk exposure and risk management are described on pages 40–45 of Essity's Annual and Sustainability Report for 2022. No significant changes have taken place that have affected the reported risks.
Risks in conjunction with company acquisitions are analyzed in the due diligence processes that Essity carries out prior to all acquisitions. In cases where acquisitions have been carried out that may affect the assessment of Essity's risk exposure, these are described under the heading "Events during the quarter" in the interim and year-end reports.

Distribution by level for measurement at fair value
| SEKm | Carrying amount in the balance sheet |
Measured at fair value through profit or loss |
Derivatives used for hedge accounting |
Financial assets measured at fair value through OCI |
Financial liabilities measured at amortized cost |
value by level1 | Of which fair |
|---|---|---|---|---|---|---|---|
| June 30, 2023 | 1 | 2 | |||||
| Derivatives | 2,518 | 1,854 | 664 | - | - | - | 2,518 |
| Non-current financial assets | 100 | - | - | 100 | - | 100 | - |
| Total assets | 2,618 | 1,854 | 664 | 100 | - | 100 | 2,518 |
| Derivatives | 7,979 | 1,446 | 6,533 | - | - | - | 7,979 |
| Financial liabilities | |||||||
| Current financial liabilities | 24,318 | - | - | 24,318 | - | - | |
| Non-current financial liabilities | 51,722 | 25,546 | - | - | 26,176 | - | 25,546 |
| Total liabilities | 84,019 | 26,992 | 6,533 | - | 50,494 | - | 33,525 |
| December 31, 2022 | |||||||
| Derivatives | 4,416 | 1,631 | 2,785 | - | - | - | 4,416 |
| Non-current financial assets | 92 | - | - | 92 | - | 92 | - |
| Total assets | 4,508 | 1,631 | 2,785 | 92 | - | 92 | 4,416 |
| Derivatives | 6,126 | 765 | 5,361 | - | - | - | 6,126 |
| Financial liabilities | |||||||
| Current financial liabilities | 12,501 | 4,489 | - | - | 8,012 | - | 4,489 |
| Non-current financial liabilities | 54,090 | 23,763 | - | - | 30,327 | - | 23,763 |
| Total liabilities | 72,717 | 29,017 | 5,361 | - | 38,339 | - | 34,378 |
1 No financial instruments have been classified to level 3
The total fair value of the above financial liabilities, excluding lease liabilities, is SEK 75,647m (64,324). The fair value of trade receivables, other current and non-current receivables, cash and cash equivalents, trade payables and other current and noncurrent liabilities is estimated to be equal to their carrying amount.
No transfers between level 1 and 2 were made during the period.
On February 2, 2022, Essity acquired the USA-based professional wiping and cleaning company Legacy Converting, Inc. The purchase price allocation for this acquisition has been finalized. No significant adjustments were made compared with the preliminary purchase price allocation.
On August 1, 2022, Essity acquired the Australian company Modibodi, a leading leakproof apparel company. The purchase price allocation for this acquisition has not yet been finalized. No significant adjustments have been made compared with the preliminary purchase price allocation presented in the Annual and Sustainability Report for 2022.
On September 1, 2022, Essity acquired the Canadian company Knix, a leading supplier of leakproof apparel for periods and incontinence. The purchase price allocation for this acquisition has not yet been finalized. No significant adjustments have been made compared with the preliminary purchase price allocation presented in the Annual and Sustainability Report for 2022.

Guidelines for Alternative Performance Measures (APMs) for companies with securities listed on a regulated market in the EU have been issued by ESMA (European Securities and Markets Authority). These guidelines are to be applied for APMs not supported under IFRS.
This half-year report refers to a number of performance measures not defined in IFRS. These performance measures are used to help investors, management and other stakeholders analyze the company's operations. These non-IFRS measures may differ from similarly titled measures among other companies. Essity's Annual and Sustainability Report for 2022, pages 82–86, describes the various non-IFRS performance measures that are used as a complement to the financial information presented in accordance with IFRS. Tables are presented below that show how the performance measures have been calculated.
| SEKm | 2306 | 2212 |
|---|---|---|
| Total assets | 221,603 | 210,600 |
| -Financial assets | -15,363 | -11,317 |
| -Non-current non-interest bearing liabilities | -10,280 | -10,405 |
| -Current non-interest bearing liabilities | -46,760 | -49,445 |
| Capital employed | 149,200 | 139,433 |
| SEKm | 2023:2 | 2023:1 | 2022:4 | 2022:3 | 2022:2 |
|---|---|---|---|---|---|
| Health & Medical | 37,223 | 34,944 | 34,557 | 35,708 | 34,799 |
| Consumer Goods | 82,035 | 77,776 | 76,672 | 81,936 | 73,267 |
| Professional Hygiene | 28,467 | 27,722 | 27,911 | 30,622 | 28,750 |
| Other | 1,475 | -4,651 | 293 | -326 | -950 |
| Capital employed | 149,200 | 135,791 | 139,433 | 147,940 | 135,866 |
| SEKm | 2306 | 2212 |
|---|---|---|
| Inventories | 28,027 | 28,888 |
| Trade receivables | 28,444 | 25,990 |
| Other current receivables | 5,152 | 5,761 |
| Trade payables | -21,760 | -25,644 |
| Other current liabilities | -22,454 | -20,995 |
| Other | 715 | 33 |
| Working capital | 18,124 | 14,033 |
| SEKm | 2306 | 2212 |
|---|---|---|
| Surplus in funded pension plans | 2,845 | 1,965 |
| Non-current financial assets | 140 | 123 |
| Current financial assets | 5,865 | 4,941 |
| Cash and cash equivalents | 6,513 | 4,288 |
| Financial assets | 15,363 | 11,317 |
| Non-current financial liabilities | 56,054 | 58,242 |
| Provisions for pensions | 2,517 | 2,671 |
| Current financial liabilities | 25,916 | 13,273 |
| Financial liabilities | 84,487 | 74,186 |
| Net debt | 69,124 | 62,869 |

| SEKm | 2306 | 2206 | 2023:2 | 2022:2 |
|---|---|---|---|---|
| Operating profit | 8,060 | 3,517 | 3,901 | 2,367 |
| -Amortization of acquisition-related intangible assets | 567 | 539 | 281 | 276 |
| -Depreciation/amortization | 3,275 | 2,993 | 1,652 | 1,526 |
| -Depreciation right-of-use asset | 580 | 523 | 295 | 266 |
| -Impairment | 37 | 7 | 1 | 4 |
| -Items affecting comparability - impairment net | 57 | 1,426 | 120 | 297 |
| -Items affecting comparability - impairment of acquisition-related intangible assets | 33 | 257 | 33 | 7 |
| EBITDA | 12,609 | 9,262 | 6,283 | 4,743 |
| -Items affecting comparability excluding depreciation/amortization and impairment | 342 | 245 | 366 | 211 |
| Adjusted EBITDA | 12,951 | 9,507 | 6,649 | 4,954 |
| SEKm | 2306 | 2206 | 2023:2 | 2022:2 |
|---|---|---|---|---|
| Operating profit | 8,060 | 3,517 | 3,901 | 2,367 |
| -Amortization of acquisition-related intangible assets | 567 | 539 | 281 | 276 |
| -Items affecting comparability - impairment of acquisition-related intangible assets | 33 | 257 | 33 | 7 |
| -Operating profit before amortization and impairment of acquisition-related | ||||
| intangible assets (EBITA) | 8,660 | 4,313 | 4,215 | 2,650 |
| EBITA margin (%) | 10.0 | 6.0 | 9.6 | 7.0 |
| -Items affecting comparability - cost of goods sold | 317 | 1,466 | 355 | 383 |
| -Items affecting comparability - sales, general and administration | 82 | 205 | 131 | 125 |
| Adjusted EBITA | 9,059 | 5,984 | 4,701 | 3,158 |
| Adjusted EBITA margin (%) | 10.4 | 8.3 | 10.7 | 8.3 |
| SEKm | 2306 | 2206 | 2023:2 | 2022:2 |
|---|---|---|---|---|
| Health & Medical | ||||
| Operating cash surplus | 2,186 | 1,935 | 1,184 | 891 |
| Change in working capital | -1,298 | -959 | -722 | -604 |
| Investment in non-current assets, net | -353 | -364 | -185 | -217 |
| Restructuring costs, etc. | 63 | 50 | 14 | 37 |
| Operating cash flow before investments in operating assets through leases | 598 | 662 | 291 | 107 |
| Investment in operating assets through leases | -42 | -33 | -17 | -2 |
| Operating cash flow | 556 | 629 | 274 | 105 |
| Consumer Goods | ||||
| Operating cash surplus | 7,311 | 5,625 | 3,645 | 2,943 |
| Change in working capital | -2,967 | -327 | -1,529 | -578 |
| Investment in non-current assets, net | -1,759 | -1,676 | -905 | -853 |
| Restructuring costs, etc. | -277 | -140 | -219 | -82 |
| Operating cash flow before investments in operating assets through leases | 2,308 | 3,482 | 992 | 1,430 |
| Investment in operating assets through leases | -240 | -145 | -55 | -67 |
| Operating cash flow | 2,068 | 3,337 | 937 | 1,363 |
| Professional Hygiene | ||||
| Operating cash surplus | 4,141 | 2,632 | 2,221 | 1,503 |
| Change in working capital | -467 | -971 | 82 | -300 |
| Investment in non-current assets, net | -711 | -523 | -371 | -296 |
| Restructuring costs, etc. | -260 | -222 | -139 | -134 |
| Operating cash flow before investments in operating assets through leases | 2,704 | 916 | 1,793 | 773 |
| Investment in operating assets through leases | 18 | -46 | -1 | -33 |
| Operating cash flow | 2,722 | 870 | 1,792 | 740 |

| SEKm | 2306 | 2023:2 |
|---|---|---|
| Health & Medical | ||
| Organic sales growth | 1,100 | 489 |
| Acquisitions | 0 | 0 |
| Sales growth including organic sales growth and acquisitions | 1,100 | 489 |
| Divestments | 0 | 0 |
| Exchange rate effect1 | 784 | 418 |
| Recognized change | 1,884 | 907 |
| Consumer Goods | ||
| Organic sales growth | 4,613 | 1,324 |
| Acquisitions | 910 | 513 |
| Sales growth including organic sales growth and acquisitions | 5,523 | 1,837 |
| Divestments | 0 | 0 |
| Exchange rate effect1 | 3,174 | 1,537 |
| Recognized change | 8,697 | 3,374 |
| Professional Hygiene | ||
| Organic sales growth | 2,565 | 988 |
| Acquisitions | 23 | 1 |
| Sales growth including organic sales growth and acquisitions | 2,588 | 989 |
| Divestments | 0 | 0 |
| Exchange rate effect1 | 1,457 | 739 |
| Recognized change | 4,045 | 1,728 |
| Essity | ||
| Organic sales growth | 8,278 | 2,793 |
| Acquisitions | 932 | 512 |
| Sales growth including organic sales growth and acquisitions | 9,210 | 3,305 |
| Divestments | 0 | 0 |
| Exchange rate effect1 | 5,416 | 2,696 |
| Recognized change | 14,626 | 6,001 |
| 1Consists solely of currency translation effects |
Essity Aktiebolag (publ), Box 200, SE-101 23 Stockholm, Sweden. www.essity.com. Corp. Reg. No. 556325-5511 25
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.